



(51) International Patent Classification:
C07D 295/03 (2006.01) A61K 31/5375 (2006.01)

(21) International Application Number:
PCT/US2021/042412

(22) International Filing Date:
20 July 2021 (20.07.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/055,235 22 July 2020 (22.07.2020) US
63/118,431 25 November 2020 (25.11.2020) US

(71) Applicant: **RENEO PHARMACEUTICALS, INC.**
[US/US]; 12230 El Camino Real, Suite 230, San Diego, California 92130 (US).

(72) Inventors: **DEL RIO GANCEDO, Susana**; 250 Cambridge Science Park, Milton Road, Cambridge Cambridgeshire CB4 0WE (GB). **SULEIMAN, Osama**; 250 Cambridge Science Park, Milton Road, Cambridge Cambridgeshire CB4 0WE (GB). **SHARP, Emma**; 250 Cam-

bridge Science Park, Milton Road, Cambridge Cambridgeshire CB4 0WE (GB). **BALOGH, Cristina**; 250 Cambridge Science Park, Milton Road, Cambridge Cambridgeshire CB4 0WE (GB). **LEE, Rachael**; P.O. Box 1, Belasis Avenue, Billingham Durham TS23 1LB (GB). **MACRAE, Julie**; 12230 El Camino Real, Suite 230, San Diego, California 92130 (US). **FEEDER, Neil**; 12230 El Camino Real, Suite 230, San Diego, California 92130 (US).

(74) Agent: **ZUNIC, Valentin B.**; WILSON SONSINI, 650 Page Mill Road, Palo Alto, California 94304 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: CRYSTALLINE PPAR-DELTA AGONIST




Figure 1

(57) Abstract: Described herein is crystalline sodium (E)-2-(4-((3-(4-fluorophenyl)-3-(4-(3-morpholinoprop-1-yn-1-yl)phenyl)allyloxy)-2-methylphenoxy)acetate, uses of such crystalline material in the preparation of pharmaceutical compositions for the treatment of diseases or conditions that would benefit by administration with a PPAR δ agonist compound.

[Continued on next page]

WO 2022/020376 A1

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*